Pricing Log in Create free account
Saturday 17 October 2026 Export KMDA’s income statement to Excel — free account

Kamada Ltd.

KMDA Healthcare Drug Manufacturers Specialty & Generic

Kamada Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $180.5 million, up 12.1% from fiscal 2024. In the quarter to June 2026, revenue grew 22.7%, EPS grew 23.1%, free cash flow grew 165.7% and total debt fell 38.8%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

7.77 0.06 −0.77%
Market cap
$451.7M
P/E
20.4×
Fwd P/E
0.0×
Dividend yield
5.41%
F-score
7/9
Altman Z
3.33
Beneish M
−2.35
Dividend safety
50/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 1.65
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — 2 —
Insider Ownership 45.31%

Capital & Financial Ratios $m

Market Cap 451.71
Revenue 191.85
Net Income 22.25
Free Cash Flow 26.32
Net Debt (64.10)
Current Ratio 4.06 (at or above 1.5: strong)
Debt/Equity 0.02 (at or below 0.5: strong)
P/E ratio 20.45
Fwd P/E 0.00
P/S ratio 2.34
P/B ratio 1.67
Past 5Y EPS Growth (1.63%) (below 0%: weak)
This Y EPS Growth 30.95% (at or above 15%: strong)
Next Y EPS Growth 20.77% (at or above 15%: strong)
Next Y revenue growth 9.48%
Next 5Y EPS Growth 21.04% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.1×, against a ten-year median of 1.7×; over the ten years it ranged from 0.8× in 2017 to 3.1× in 2017.
P/E against its own 10 years 55.42%
10-year low 10-year high
P/S against its own 10 years 72.06%
10-year low 10-year high
P/B against its own 10 years 50.57%
10-year low 10-year high
EV/Sales against its own 10 years 74.97%
10-year low 10-year high
EV/FCF against its own 10 years 44.20%
10-year low 10-year high

Dividends

Payout Ratio 1.11
Annual Dividend Rate 0.42
Annual Dividend Yield 5.41%
total individual payouts
2026 0.42
0.25
0.17
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 56 78 75 70
Receivables 26 27 33 43
Inventory 88 79 85 87
Other — — — —
170 184 193 200
2023 2024 2025 Q'26
Payables 33 37 35 41
ST’ Debt 15 10 10 6
Other — — — —
50 49 47 49

Compound Annual Growth %

10y 5y 3y
Sales 9.95% 6.25% 11.74%
Cash Flow 0.00% 5.94% (3.75%)
Earnings 0.00% 3.34% 0.00%
Book Value 14.01% 8.54% 15.20%

Revenue $m

Mar Jun Sep Dec Year
’26 45 55 — — —
’25 44 45 47 45 180
’24 38 42 42 39 161
’23 31 37 38 36 143
’22 28 24 32 45 129
’21 25 24 23 31 104
’20 33 33 35 32 133
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 0 18 — — —
’25 (1) 8 10 8 25
’24 1 14 22 10 48
’23 (3) 2 1 4 4
’22 5 11 5 7 29
’21 2 (3) (3) (5) (9)
’20 (2) 11 (2) 13 19
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (1) 16 — — —
’25 (2) 6 7 5 16
’24 (2) 11 20 7 37
’23 (4) 1 (1) 2 (2)
’22 5 10 4 6 25
’21 2 (5) (4) (6) (13)
’20 (3) 10 (4) 11 14
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 0.07 0.16 — — —
’25 0.07 0.13 0.09 0.06 0.35
’24 0.04 0.08 0.07 0.07 0.25
’23 (0.04) 0.04 0.06 0.09 0.15
’22 (0.04) (0.09) 0.01 0.07 (0.05)
’21 0.06 0.02 (0.02) (0.11) (0.05)
’20 0.12 0.08 0.15 0.04 0.38
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 3.26 3.75 4.35 4.91 4.40 5.11 3.72 4.02 4.74 5.54

Analyst estimates 2026–2028

Powerpack
High 6.29 8.61 6.45 8.00 13.33 8.16 6.88 6.35 6.53 9.15
People
People Employees 377 413 408 429 408 357 380 378 420 462
Revenue/emp, $m 0.21 0.25 0.28 0.30 0.33 0.29 0.34 0.38 0.38 0.39
Income, $m
Income, $m Revenue 77 103 114 127 133 104 129 143 161 180
Gross margin, % 27.56 31.21 36.23 39.11 35.69 29.26 36.11 38.94 43.47 42.34
EBT (5) 7 20 23 19 (2) (2) 8 13 23
EBT margin, % (6.47) 6.97 17.77 18.07 13.93 (1.82) (1.75) 5.91 8.28 13.00
Net income (7) 7 22 22 17 (2) (2) 8 14 20
Depreciation 4 4 4 5 5 6 12 13 14 15
Per share, $
Per share, $ Revenue 2.13 2.71 2.84 3.15 3.02 2.31 2.89 2.92 2.80 3.13
Earnings (0.18) 0.18 0.55 0.55 0.39 (0.05) (0.05) 0.17 0.25 0.35
Cash flow 0.05 0.10 0.26 0.68 0.43 (0.20) 0.64 0.09 0.83 0.44
Capex (0.07) (0.11) (0.07) (0.06) (0.12) (0.08) (0.08) (0.12) (0.19) (0.17)
Free cash flow (0.02) (0.01) 0.19 0.63 0.31 (0.28) 0.55 (0.03) 0.64 0.27
Book value 1.83 2.36 2.79 3.36 4.05 3.95 3.93 5.00 4.51 4.67
Shares, m 36 38 40 40 44 45 45 49 57 58
Valuation, ×
Valuation, × P/E 0.00 28.24 9.09 12.65 16.62 0.00 0.00 38.50 23.42 20.17
P/S 2.75 1.77 1.76 2.17 2.15 2.84 1.44 2.11 2.18 2.26
P/B 3.19 2.04 1.79 2.04 1.60 1.67 1.06 1.23 1.35 1.51
EV/Sales 2.40 1.37 1.33 1.59 1.33 3.03 1.54 1.90 1.82 1.95
EV/FCF (265.24) (283.02) 19.75 8.00 12.99 (25.02) 8.02 (177.28) 7.94 22.50
Cash, $m
Cash, $m Operating cash flow 2 4 11 28 19 (9) 29 4 48 25
Capex (3) (4) (3) (2) (5) (4) (4) (6) (11) (10)
Free cash flow (1) 0 8 25 14 (13) 25 (2) 37 16
Balance, $m
Balance, $m Working capital 50 67 87 111 153 76 63 120 135 146
Total debt 2 2 1 1 0 38 47 15 10 10
Net debt (27) (41) (49) (73) (109) 19 13 (41) (68) (66)
Shareholders’ equity 67 89 112 135 179 177 176 244 259 269
Returns, %
Returns, % ROA (6.68) 6.22 17.14 14.27 8.92 (0.84) (0.72) 2.45 3.98 5.38
ROIC (8.59) 9.60 19.13 22.91 17.26 (0.22) 1.50 3.09 6.55 8.06
ROE (9.67) 8.83 22.09 17.97 10.92 (1.25) (1.32) 3.94 5.74 7.64
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Kamada Ltd. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
IRWD Ironwood Pharmaceuticals, Inc. $623.0M 4.4× 2.8× +32.62% (above 0%: growing) +106.67% (above 0%: growing) +486.70% (above 0%: growing) 100.00% 70.16% Compare
AQST Aquestive Therapeutics, Inc. $509.6M — (loss-making) — (loss-making) +38.15% (above 0%: growing) n/m −20.35% (below 0%: shrinking) 70.93% (59.51%) Compare
EVO Evotec AG $504.4M — (loss-making) — (loss-making) −12.98% (below 0%: shrinking) n/m −9,727.20% (below 0%: shrinking) (1.00%) (77.50%) Compare
EOLS Evolus, Inc. $500.0M — (loss-making) — (loss-making) +21.18% (above 0%: growing) n/m +84.90% (above 0%: growing) 68.00% (5.40%) Compare
TLRY Tilray Brands, Inc. $474.4M — (loss-making) — (loss-making) +22.74% (above 0%: growing) n/m −36.60% (below 0%: shrinking) 30.14% (9.35%) Compare
KMDA Kamada Ltd. $451.7M 20.4× — (loss-making) +22.72% (above 0%: growing) +23.08% (above 0%: growing) +165.71% (above 0%: growing) 40.91% 17.32%
TKNO Alpha Teknova, Inc. $408.0M — (loss-making) — (loss-making) +18.45% (above 0%: growing) n/m +74.18% (above 0%: growing) 40.09% (23.72%) Compare
EBS Emergent Biosolutions Inc. $368.1M — (loss-making) — (loss-making) +66.29% (above 0%: growing) n/m −47.68% (below 0%: shrinking) 58.56% (53.39%) Compare
CGC Canopy Growth Corporation $311.2M — (loss-making) — (loss-making) +12.41% (above 0%: growing) n/m −117.60% (below 0%: shrinking) 27.40% (27.24%) Compare
Median of peers $487.2M — — +21.96% — −28.47% 49.32% (25.48%)

All 86 Drug Manufacturers Specialty & Generic stocks →

Kamada Ltd. (KMDA) key facts

  • Strength: Kamada Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $180.5 million, up 12.1% from fiscal 2024.
  • Strength: Net income was $20.2 million, or $0.35 per share (basic), a net margin of 11.2%.
  • Kamada Ltd. (KMDA) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, KMDA traded at $7.77, a market capitalization of $451.7 million.
  • At that price the stock trades at 20.4× trailing-twelve-month earnings and 2.3× sales; its P/E is higher than 55% of its own readings over the past ten years.
  • Kamada Ltd. pays an annual dividend of $0.42 per share, a yield of 5.41%, with a payout ratio of 110.5%.
  • Return on equity was 7.64% and debt-to-equity 0.02.
  • Its Piotroski F-score is 7 out of 9 and its Altman Z-score is 3.33 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Kamada Ltd. (KMDA) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/KMDA · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com